Pulmonary Tuberculosis Clinical Trial
— TPEOfficial title:
Descriptive Epidemiological Study of Hospitalized Children for Pulmonary Tuberculosis at Strasbourg University Hospitals
| NCT number | NCT06110533 |
| Other study ID # | 8907 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | April 4, 2023 |
| Est. completion date | April 14, 2024 |
Pulmonary tuberculosis is the most common form of tuberculosis in children; According to the WHO, tuberculosis pulmonary tuberculosis in children represents approximately 80% of all cases of tuberculosis in children. In 2020, there were approximately 1.0 million new cases of pulmonary tuberculosis among children worldwide. In France, childhood tuberculosis remains a rare disease; the most recent data show a rate of 3.3 cases per 100,000 inhabitants among children under 15 years old in 2019. Pulmonary tuberculosis in children can lead to complications such as bronchiectasis and pneumothorax. Children living in homes where an adult has a active tuberculosis, or children with diseases chronic, malnourished or suffering from HIV are more likely to contract tuberculosis. The aim of this research is to determine the incidence, identify the risk factors as well as the clinical forms of pulmonary tuberculosis in children hospitalized at Strasbourg University Hospitals between 2012 and 2022.
| Status | Recruiting |
| Enrollment | 50 |
| Est. completion date | April 14, 2024 |
| Est. primary completion date | April 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 17 Years |
| Eligibility | Inclusion Criteria: - Child (1 to 17 years old) - Child hospitalized for pulmonary tuberculosis at Strasbourg University Hospital between January 1, 2012 and December 31, 2022. - Child and/or his/her parental authority who have not expressed their opposition to the reuse of data for scientific research purposes. Exclusion Criteria: - Subject and/or their parental authority having expressed their opposition to the re-use of the child's data for scientific research purposes. |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) - CHU de Strasbourg - France | Strasbourg |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Strasbourg, France |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence and risk factors for pulmonary tuberculosis in children hospitalized at Strasbourg University Hospital between 2012 and 2022 | 1 month after hospitalization for pulmonary tuberculosis |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02736864 -
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae
|
N/A | |
| Not yet recruiting |
NCT04055441 -
A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
|
||
| Completed |
NCT02349841 -
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
|
Phase 2 | |
| Completed |
NCT01927159 -
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT01691534 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
|
Phase 2 | |
| Completed |
NCT00803322 -
Improving Community Based Tuberculosis Care in Ethiopia
|
Phase 4 | |
| Completed |
NCT00834353 -
Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
|
N/A | |
| Withdrawn |
NCT03277742 -
Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
|
N/A | |
| Completed |
NCT00057434 -
Vitamin A Therapy for Tuberculosis
|
Phase 3 | |
| Not yet recruiting |
NCT06192160 -
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2 | |
| Recruiting |
NCT06127641 -
Rehabilitation of People With Post-tuberculosis Lung Disease
|
N/A | |
| Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
| Completed |
NCT04550832 -
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
|
Phase 2 | |
| Completed |
NCT02912832 -
Prospective Assessment of TBDx Feasibility
|
N/A | |
| Completed |
NCT01215851 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)
|
Phase 2 | |
| Recruiting |
NCT01503099 -
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
|
N/A | |
| Completed |
NCT04608955 -
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
|
Phase 2 | |
| Recruiting |
NCT05046366 -
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
|
||
| Completed |
NCT05896930 -
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
|
Phase 2 | |
| Completed |
NCT02279875 -
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
|
Phase 2 |